In the News
JDRF will contribute up to $500,000 in funds to finance preclinical studies on the MAILPAN® bioartificial pancreas
Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes
$2.45 million USD awarded to advance Sernova’s Cell Pouch System(TM) (CPS) technologies in a US FDA Clinical Trial with Initiation Scheduled for the Second Half of 2016
JDRF presented three prestigious research awards to three experts whose groundbreaking research is accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications.
The JDRF Revolution Ride to Defeat Diabetes, presented by Sun Life Financial, is taking place through September and October in 19 cities across Canada and will engage over 15,000 people who are ready to make a difference for those living with type 1 diabetes (T1D).
JDRF Canada salutes the recent discovery of Dr. Pere Santamaria and his team who have identified a novel approach to halt and possibly reverse the autoimmune attack that triggers type 1 diabetes (T1D), causing the destruction of insulin-producing pancreatic beta cells in T1D patients.
JDRF and Sanofi Announce Expansion of their Joint Research Collaboration to Include Development of Glucose Responsive Insulin Therapies for Treatment of Insulin-Dependent Diabetes
JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi US Services Inc., a subsidiary of Sanofi, one of the leading insulin manufacturers and a global pharmaceutical company, have entered into new agreements with four research organizations under ...
Researchers Show Novel Material Encapsulated Human Islet Cells Can Halt Type 1 Diabetes for Six Months
Researchers from the Massachusetts Institute of Technology (MIT), Boston Children’s Hospital, and several other institutions supported with JDRF funding have shown encapsulated human islet cells transplanted into mice can effectively halt type 1 diabetes (T1D) for up to six months without causing ...